BACE1 and Alzheimer disease: Collectively, low-dose BACE1-specific inhibitor trials initiated at the earliest preclinical stage of AD is most promising, while evaluating the cognitive efficacy (if any) in asymptomatic individuals at a risk of developing AD is challenging (Mortamais et al., 2017).